Invitrogen Begins Global Distribution of Custom Oligonucleotides
News Dec 01, 2005
Invitrogen Corporation has announced the introduction of tube-based oligos at the 25nmole starting synthesis scale.
Invitrogen claims that, the tube-based offerings deliver significant value to the life science market, enabling researchers to effectively procure twice as much quantity of high-quality primers for the same competitive price they were previously paying for tube-based oligos synthesized at the 10nmole starting synthesis scale.
This scale change is a further outcome of the collaboration with Illumina. Invitrogen Corporation and Illumina, Inc. are collaborating to manufacture, sell, and support oligo products in both plates and tubes to researchers worldwide.
Coupled with Invitrogen's global distribution and customer support, Illumina's oligo manufacturing technology is designed to provide a broad array of superior quality oligonucleotide products and services.
Invitrogen and Illumina announced in December 2004 a strategic alliance to combine their DNA synthesis, distribution and marketing capabilities.
"This collaboration has allowed Invitrogen to create a fully automated synthesis system by applying state of the art technology for plates and tubes," said Nicolas Barthelemy, Invitrogen Senior Vice President, Operations.
"Combined with our world-class customer service and technical support, we are providing increased value to researchers by offering superior oligos at very competitive prices."
The Invitrogen and Illumina custom DNA oligo production processes are driven by Illumina's proprietary synthesis platform.
In addition to synthesis capabilities, Illumina's automated manufacturing process results in accuracy and efficiency from order entry to documentation and shipping.
Invitrogen and Illumina have coordinated respective enterprise IT systems to integrate oligo ordering, synthesis and distribution.
"As a part of our collaboration, we have significantly expanded synthesis capacity, post-processing infrastructure, and automated order management," said John Stuelpnagel, Illumina Senior Vice President and COO.
"Our customers will benefit from the increased range and availability of products brought about by these efforts."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.